{"id":7276,"date":"2024-11-07T08:00:00","date_gmt":"2024-11-07T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/"},"modified":"2024-11-07T08:00:00","modified_gmt":"2024-11-07T07:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-september-2024","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Nanexas fas I-studie inom NEX-22 projektet f\u00f6r typ 2-diabetes har slutf\u00f6rts f\u00f6r samtliga patienter enligt plan.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>V\u00e4sentliga h\u00e4ndelser under tredje kvartalet 2024<\/p>\n<ul>\n<li>Nanexa meddelade i augusti att bolagets fas I-studie f\u00f6r typ 2-diabetes inom NEX-22-projektet fortg\u00e5r enligt plan med ytterligare doseskalering med bolagets dep\u00e5formulering av GLP-1-analogen liraglutid.<\/li>\n<li>Nanexa meddelade i september att f\u00f6rsta patienten i tredje och sista dosgruppen i bolagets fas-I-studie med sin dep\u00e5formulering av GLP-1-analogen liraglutid doserats. Studien inleddes i juni 2024 och hittills har tv\u00e5 p\u00e5 varandra f\u00f6ljande grupper med eskalerande doser studerats.<\/li>\n<li>Nanexa meddelade att Cecilia Danckwardt-Lilliestr\u00f6m tilltr\u00e4tt som Chief Financial Officer fr\u00e5n och med 1 september 2024.<\/li>\n<\/ul>\n<p>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/p>\n<ul>\n<li>Nanexa meddelade i oktober att doseringen av den sista patienten genomf\u00f6rts enligt plan i fas-1 studien med den l\u00e5ngtidsverkande dep\u00e5formuleringen av GLP-1 analogen liraglutid med PharmaShell\u00ae (NEX-22).<\/li>\n<li>Nanexa AB meddelade i b\u00f6rjan av november att bolagets fas I-studie inom NEX-22 projektet f\u00f6r typ 2-diabetes har slutf\u00f6rts f\u00f6r samtliga patienter. Studien utv\u00e4rderar en l\u00e5ngverkande dep\u00e5formulering av GLP-1-analogen liraglutid med Nanexas patenterade PharmaShell\u00ae-system.<\/li>\n<li>Nyligen publicerade pressmeddelanden visar p\u00e5 det \u00f6kade intresset f\u00f6r long acting GLP-1 antagonister och som v\u00e4ntat forts\u00e4tter Novo Nordisk och andra att s\u00f6ka b\u00e4ttre behandlingsalternativ inom detta snabbt v\u00e4xande omr\u00e5de.<\/li>\n<\/ul>\n<p>Finansiell \u00f6versikt<\/p>\n<p>1 juli &#8211; 30 september 2024<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 6 434 (6 683) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -4 450 (-6 488) kSEK<\/li>\n<li>Periodens resultat uppgick till: -4 438 (-6 694) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,03 (-0,11) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -12 302 (-17 790) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 29 009 (20 569) kSEK<\/li>\n<\/ul>\n<p>1 januari &#8211; 30 september 2024<\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 19 844 (22 511) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -14 037 (-25 258) kSEK<\/li>\n<li>Periodens resultat uppgick till: -13 273 (-25 247) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,10 (-0,42) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -36 160 (-60 613) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 29 009 (20 569) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida: <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" rel=\"noopener\" target=\"_blank\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p>Rapportkommentar 7 november kl. 10:15<\/p>\n<p>En lives\u00e4nd kommentar med vd David Westberg h\u00e5lls den 7 november kl. 10:15 via Infront Direkt Studios och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>Rapportkommentaren kommer att finnas tillg\u00e4nglig <a href=\"https:\/\/eur01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fyoutube.com%2Flive%2FRpDs8ijnSf0&amp;data=05|02|maria.medeen%40nanexa.se|5ead842010934090421908dcfdaa744f|cf2057b571ae407dac1e06fc7f9e6904|0|0|638664155752365257|Unknown|TWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D|0|||&amp;sdata=erj1kJkf9H5VGoqIZH2aTodDtlMit1a6bQAP8ksSg%2B8%3D&amp;reserved=0\" rel=\"noopener\" target=\"_blank\">h\u00e4r.<\/a><\/p>\n<p>Rapportkommentaren kommer \u00e4ven att l\u00e4ggas upp p\u00e5 Nanexas hemsida i efterhand.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" rel=\"noopener\" target=\"_blank\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" rel=\"noopener\" target=\"_blank\">www.nanexa.com<\/a><\/p>\n<p>Bolagets Certified Adviser \u00e4r Carnegie Investment Bank AB (publ).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland Novo Nordisk och AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2024-11-07 08:00 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/a99d5d81-0899-4fbf-8d75-110fb25f94a4\/nanexa-delarsrapport-januari-september-2024.pdf\" rel=\"noopener\" target=\"_blank\">Nanexa Del\u00e5rsrapport Januari September 2024<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanexas fas I-studie inom NEX-22 projektet f\u00f6r typ 2-diabetes har slutf\u00f6rts f\u00f6r samtliga patienter enligt plan.<\/p>\n","protected":false},"template":"","class_list":["post-7276","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q3_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexas fas I-studie inom NEX-22 projektet f\u00f6r typ 2-diabetes har slutf\u00f6rts f\u00f6r samtliga patienter enligt plan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2024\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2024\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2024-11-07T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2024\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2024\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-september-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024 - Nanexa AB","og_description":"Nanexas fas I-studie inom NEX-22 projektet f\u00f6r typ 2-diabetes har slutf\u00f6rts f\u00f6r samtliga patienter enligt plan.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2024-11-07T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-september-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-september 2024"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/7276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=7276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}